Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
1.04B
Enterprise Value
2.38B
Income
40.28M
Sales
209.26M
Book/sh
15.63
Cash/sh
0.51
Employees
-
IPO
Jun 12, 2008
P/E
25.80
Forward P/E
8.53
PEG
-
P/S
4.97
P/B
0.76
P/C
23.03
P/FCF
10.20
EV/EBITDA
16.79
EV/Sales
11.37
Quick Ratio
0.22
Current Ratio
0.22
Debt/Eq
1.01
LT Debt/Eq
0.70
Option/Short
Yes / Yes
EPS (ttm)
0.46
EPS next Y
1.38
EPS next Q
0.32
EPS this Y
-10.83%
EPS next Y
4.16%
EPS next 5Y
-1.29%
EPS past 3/5Y
-34.49% -36.39%
Sales past 3/5Y
-15.44% -2.36%
EPS Y/Y TTM
20.18%
Sales Y/Y TTM
-30.18%
EPS Q/Q
-7.92%
Sales Q/Q
-33.36%
Insider Own
0.46%
Insider Trans
0.42%
Inst Own
51.31%
Inst Trans
-
ROA
1.38%
ROE
2.83%
ROIC
1.72%
Gross Margin
81.14%
Oper. Margin
67.70%
Profit Margin
19.25%
SMA20
-2.71%
SMA50
-1.64%
SMA200
-1.79%
Trades
Shs Outstand
88.09M
Shs Float
87.68M
52W High
13.83 -14.66%
52W Low
10.57 11.64%
Volatility
3.16% 2.46%
ATR (14)
0.30
RSI (14)
42.71
Beta
0.55
Rel Volume
1.22
Avg Volume
447.93K
Volume
111,502
Perf Week
-2.96%
Perf Month
3.06%
Perf Quarter
-10.12%
Perf Half Y
0.82%
Perf YTD
-6.85%
Perf Year
-10.03%
Perf 3Y
-39.72%
Perf 5Y
-44.74%
Perf 10Y
-28.55%
Prev Close
11.83
Price
11.80
Change %
-0.25%
Consensus
Hold
Avg. Price Target
$12.25
Implied Upside
+3.8%
Analysts11incl. previous ratings
Rating Distribution3 Buy · 8 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 26, 2026Initiated
CCitizens
Mkt Perform
May 13, 2025Resumed
RILY logoRB. Riley Securities
Neutral$14+18.6%
Dec 11, 2024Downgrade
RILY logoRB. Riley Securities
Neutral → Sell$15+27.1%
Nov 20, 2024Downgrade
JPM logoJJP Morgan
Overweight → Neutral$17 → $15+27.1%
Nov 19, 2024Downgrade
JJMP Securities
Mkt Outperform → Mkt Perform
Aug 26, 2024Downgrade
WFC logoWWells Fargo
Overweight → Equal Weight$18 → $17+44.1%
Aug 02, 2024Downgrade
OPY logoOOppenheimer
Outperform → Perform
Feb 02, 2024Downgrade
KKeefe Bruyette
Outperform → Mkt Perform$22 → $19+61.0%
Jan 08, 2024Downgrade
RILY logoRB. Riley Securities
Buy → Neutral$21+78.0%
Aug 04, 2023Downgrade
HHovde Group
Outperform → Market Perform$21+78.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Panossian ArmenSee RemarksAug 12 '26Buy12.691,70021,58122,489Aug 13 04:05 PM
CALDWELL PHYLLIS RDirectorMar 16 '26Buy10.772,50026,92523,500Mar 18 04:05 PM
Gero Deborah AnnDirectorMar 16 '26Buy10.782,00021,55824,411Mar 18 06:05 AM
Oaktree Specialty Lending Corp. is a closed-end investment fund, which engages in the provision of credit solutions to companies with limited access to public or syndicated capital markets. Its objective is to generate current income and capital appreciation by providing companies with solutions including first and second lien loans, unsecured and mezzanine loans, and preferred equity. The company was founded on February 15, 2007 and is headquartered in Los Angeles, CA.
CEO & Co-Chief Investment OfficerMr. Armen Panossian J.D.
PresidentMr. Mathew M. Pendo
Managing Director & Co-Portfolio Manager of Life Sciences Direct LendingDr. Aman Kumar M.D.
CFO & TreasurerMr. Christopher McKown
Chief Operating OfficerMr. Brett McKeone